Redhill Biopharma - ADR

NASDAQ:RDHL  
2.46
+0.06 (+2.50%)
Products

Redhill Biopharma's Oral Opaganib Significantly Improves Viral Clearance In Phase 2/3 Study In Severely Ill Hospitalized Covid-19 Patients

Published: 01/13/2022 15:42 GMT
Redhill Biopharma - ADR (RDHL) - Redhill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized Covid-19 Patients.
Redhill Biopharma - Results Achieved With Oral Opaganib in Severely Ill Hospitalized Patient Population With Median of 11-days From Onset of Symptoms.
Redhill Biopharma Ltd - Results Add to Opaganib's 62% Reduction in Mortality Seen in a Post-hoc Analysis of Phase 2/3 Study.